Cargando…
Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
AIM: Patients with lipodystrophy are at high risk for chronic complications of diabetes. Recently, we have reported 18 diabetic foot ulcer episodes in 9 subjects with lipodystrophy. This current study aims to determine risk factors associated with foot ulcer development in this rare disease populati...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485489/ https://www.ncbi.nlm.nih.gov/pubmed/34593051 http://dx.doi.org/10.1186/s40842-021-00132-9 |
_version_ | 1784577546145234944 |
---|---|
author | Saydam, O Ozgen Saydam, B Adiyaman, SC Sonmez Ince, M Eren, MA Keskin, FE Bilen, H Dagdeviren, M Kaya, S Akinci, G Balci, A Altay, C Bayraktar, F Oral, EA Akinci, B |
author_facet | Saydam, O Ozgen Saydam, B Adiyaman, SC Sonmez Ince, M Eren, MA Keskin, FE Bilen, H Dagdeviren, M Kaya, S Akinci, G Balci, A Altay, C Bayraktar, F Oral, EA Akinci, B |
author_sort | Saydam, O |
collection | PubMed |
description | AIM: Patients with lipodystrophy are at high risk for chronic complications of diabetes. Recently, we have reported 18 diabetic foot ulcer episodes in 9 subjects with lipodystrophy. This current study aims to determine risk factors associated with foot ulcer development in this rare disease population. METHODS: Ninety metreleptin naïve patients with diabetes registered in our national lipodystrophy database were included in this observational retrospective cohort study (9 with and 81 without foot ulcers). RESULTS: Patients with lipodystrophy developing foot ulcers had longer diabetes duration (p = 0.007), longer time since lipodystrophy diagnosis (p = 0.008), and higher HbA1c levels (p = 0.041). Insulin use was more prevalent (p = 0.003). The time from diagnosis of diabetes to first foot ulcer was shorter for patients with generalized lipodystrophy compared to partial lipodystrophy (p = 0.036). Retinopathy (p < 0.001), neuropathy (p < 0.001), peripheral artery disease (p = 0.001), and kidney failure (p = 0.003) were more commonly detected in patients with foot ulcers. Patients with foot ulcers tended to have lower leptin levels (p = 0.052). Multiple logistic regression estimated significant associations between foot ulcers and generalized lipodystrophy (OR: 40.81, 95% CI: 3.31–503.93, p = 0.004), long-term diabetes (≥ 15 years; OR: 27.07, 95% CI: 2.97–246.39, p = 0.003), and decreased eGFR (OR: 13.35, 95% CI: 1.96–90.67, p = 0.008). CONCLUSIONS: Our study identified several clinical factors associated with foot ulceration among patients with lipodystrophy and diabetes. Preventive measures and effective treatment of metabolic consequences of lipodystrophy are essential to prevent the occurrence of foot ulcers in these high-risk individuals. |
format | Online Article Text |
id | pubmed-8485489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84854892021-10-04 Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy Saydam, O Ozgen Saydam, B Adiyaman, SC Sonmez Ince, M Eren, MA Keskin, FE Bilen, H Dagdeviren, M Kaya, S Akinci, G Balci, A Altay, C Bayraktar, F Oral, EA Akinci, B Clin Diabetes Endocrinol Research Article AIM: Patients with lipodystrophy are at high risk for chronic complications of diabetes. Recently, we have reported 18 diabetic foot ulcer episodes in 9 subjects with lipodystrophy. This current study aims to determine risk factors associated with foot ulcer development in this rare disease population. METHODS: Ninety metreleptin naïve patients with diabetes registered in our national lipodystrophy database were included in this observational retrospective cohort study (9 with and 81 without foot ulcers). RESULTS: Patients with lipodystrophy developing foot ulcers had longer diabetes duration (p = 0.007), longer time since lipodystrophy diagnosis (p = 0.008), and higher HbA1c levels (p = 0.041). Insulin use was more prevalent (p = 0.003). The time from diagnosis of diabetes to first foot ulcer was shorter for patients with generalized lipodystrophy compared to partial lipodystrophy (p = 0.036). Retinopathy (p < 0.001), neuropathy (p < 0.001), peripheral artery disease (p = 0.001), and kidney failure (p = 0.003) were more commonly detected in patients with foot ulcers. Patients with foot ulcers tended to have lower leptin levels (p = 0.052). Multiple logistic regression estimated significant associations between foot ulcers and generalized lipodystrophy (OR: 40.81, 95% CI: 3.31–503.93, p = 0.004), long-term diabetes (≥ 15 years; OR: 27.07, 95% CI: 2.97–246.39, p = 0.003), and decreased eGFR (OR: 13.35, 95% CI: 1.96–90.67, p = 0.008). CONCLUSIONS: Our study identified several clinical factors associated with foot ulceration among patients with lipodystrophy and diabetes. Preventive measures and effective treatment of metabolic consequences of lipodystrophy are essential to prevent the occurrence of foot ulcers in these high-risk individuals. BioMed Central 2021-10-01 /pmc/articles/PMC8485489/ /pubmed/34593051 http://dx.doi.org/10.1186/s40842-021-00132-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Saydam, O Ozgen Saydam, B Adiyaman, SC Sonmez Ince, M Eren, MA Keskin, FE Bilen, H Dagdeviren, M Kaya, S Akinci, G Balci, A Altay, C Bayraktar, F Oral, EA Akinci, B Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy |
title | Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy |
title_full | Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy |
title_fullStr | Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy |
title_full_unstemmed | Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy |
title_short | Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy |
title_sort | risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485489/ https://www.ncbi.nlm.nih.gov/pubmed/34593051 http://dx.doi.org/10.1186/s40842-021-00132-9 |
work_keys_str_mv | AT saydamo riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT ozgensaydamb riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT adiyamansc riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT sonmezincem riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT erenma riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT keskinfe riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT bilenh riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT dagdevirenm riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT kayas riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT akincig riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT balcia riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT altayc riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT bayraktarf riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT oralea riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy AT akincib riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy |